Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON +4.03%96 Days Inventory is 156.35 as of Mar. 2026, which is 18% above its 10-year median of 132.42. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,021.26 (Fairly Valued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Highnoon Laboratories ranks better than 53.69% on this metric.
The historical rank and industry rank for Highnoon Laboratories's Days Inventory or its related term are showing as below:
KAR:HINOON'
s Days Inventory Range Over the Past 10 Years
Min: 115.03 Med: 132.42 Max: 157.66
Current: 155.8
During the past 13 years, Highnoon Laboratories's highest Days Inventory was 157.66. The lowest was 115.03. And the median was 132.42.
KAR:HINOON's Days Inventory is ranked better than 53.69% of 922
companies
in the Drug Manufacturers industry
Industry Median: 164.58
vs KAR:HINOON: 155.80
Inventory Turnover measures how fast the company turns over its inventory within a year.
Highnoon Laboratories's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.58.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Highnoon Laboratories's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.72.
Highnoon Laboratories (KAR:HINOON) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Highnoon Laboratories's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Highnoon Laboratories's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Highnoon Laboratories Days Inventory Related Terms
Highnoon Laboratories Days Inventory Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Days Inventory distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a Days Inventory of 156.35 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Highnoon Laboratories and its competitors. This is 18% above median its historical median of 132.42. Over the past decade, Highnoon Laboratories' Days Inventory has ranged from 115.03 to 157.66. According to the industry distribution chart, Highnoon Laboratories ranks #427 out of 922 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Highnoon Laboratories' Days Inventory too high?
Highnoon Laboratories' current Days Inventory of 156.35 is 18% above median its 10-year median of 132.42. Over the past 10 years, this metric has ranged from a low of 115.03 to a high of 157.66. The Drug Manufacturers industry median Days Inventory is 164.58. Highnoon Laboratories' value of 156.35 is 5% below this industry median. Based on the distribution chart, Highnoon Laboratories ranks #427 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #427 out of 922 companies for Days Inventory. This puts Highnoon Laboratories in the upper half of its industry. The industry median Days Inventory is 164.58. Highnoon Laboratories' value of 156.35 is 5% below this benchmark. Historically, Highnoon Laboratories' own Days Inventory has ranged from 115.03 to 157.66 over the past decade. While the company's 10-year median is 132.42 vs. the industry median of 164.58, Highnoon Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.58, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current Days Inventory of 156.35 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current Days Inventory is 156.35, which is 18% above median its own 10-year median of 132.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,021.26, compared to a current price of ₨999.95 — trading 2.1% below its estimated fair value. The current Days Inventory is 156.35, which is 18% above median its 10-year median of 132.42 and 5% below the Drug Manufacturers industry median of 164.58. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Days Inventory is 156.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨999.95 is trading 2.1% below its estimated GF Value™ of ₨1,021.26.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Days Inventory: 156.35 (18% above median its 10-year median of 132.42)
GF Value™: ₨1,021.26 vs. price of ₨999.95 (2.1% below fair value)
Industry Position: 5% below the Drug Manufacturers median (#427 of 922)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
